多沙普仑对比安慰剂用于早产儿:国际双盲多中心随机对照试验(DOXA试验)的研究方案
DOXA试验为在荷兰、比利时和加拿大开展的双盲、多中心、随机、安慰剂对照试验,计划纳入396例胎龄低于29周、对无创呼吸支持和咖啡因无反应的早产儿呼吸暂停患儿,随机接受多沙普仑或安慰剂治疗,主要结局为校正年龄18至24个月时的死亡或严重残疾复合结局,以评估多沙普仑的安全性和有效性。
要点
- 多沙普仑可能减少早产儿低氧血症发作和有创机械通气需求,但缺乏高质量试验证据。
- 计划纳入396例胎龄低于29周、对无创呼吸支持和咖啡因无反应的早产儿呼吸暂停患儿。
- 主要结局为校正年龄18至24个月时的死亡或严重残疾复合结局。
核心结论
- 多沙普仑有潜力通过改善呼吸来改善新生儿结局,但需权衡安全顾虑与有创机械通气的潜在风险。
- 多沙普仑能否改善长期结局尚不清楚,这构成本试验的临床均势。
- 该国际多中心试验将为多沙普仑治疗早产儿呼吸暂停的有效性和安全性提供所需的高质量证据。
研究设计与样本
- DOXA试验为在荷兰、比利时和加拿大开展的双盲、多中心、随机、安慰剂对照试验。
- 计划纳入396例胎龄低于29周、对无创呼吸支持和咖啡因无反应的早产儿呼吸暂停患儿,随机接受多沙普仑治疗或安慰剂。
- 分析将按意向性治疗原则进行。
主要发现
- 主要结局为校正年龄18至24个月时的死亡或严重残疾,严重残疾定义为认知迟缓、脑性瘫痪、重度听力丧失或双侧失明。
- 次要结局包括短期新生儿疾病,包括机械通气持续时间、支气管肺发育不良和坏死性小肠结肠炎,以及住院死亡率、不良反应、药代动力学和成本效益。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Apnoea of prematurity (AOP) is one of the most common diagnoses among preterm infants. AOP often leads to hypoxemia and bradycardia which are associated with an increased risk of death or disability. In addition to caffeine therapy and non-invasive respiratory support, doxapram might be used to reduce hypoxemic episodes and the need for invasive mechanical ventilation in preterm infants, thereby possibly improving their long-term outcome. However, high-quality trials on doxapram are lacking. The DOXA-trial therefore aims to investigate the safety and efficacy of doxapram compared to placebo in reducing the composite outcome of death or severe disability at 18 to 24 months corrected age. METHODS: The DOXA-trial is a double blinded, multicentre, randomized, placebo-controlled trial conducted in the Netherlands, Belgium and Canada. A total of 396 preterm infants with a gestational age below 29 weeks, suffering from AOP unresponsive to non-invasive respiratory support and caffeine will be randomized to receive doxapram therapy or placebo. The primary outcome is death or severe disability, defined as cognitive delay, cerebral palsy, severe hearing loss, or bilateral blindness, at 18-24 months corrected age. Secondary outcomes are short-term neonatal morbidity, including duration of mechanical ventilation, bronchopulmonary dysplasia and necrotising enterocolitis, hospital mortality, adverse effects, pharmacokinetics and cost-effectiveness. Analysis will be on an intention-to-treat principle. DISCUSSION: Doxapram has the potential to improve neonatal outcomes by improving respiration, but the safety concerns need to be weighed against the potential risks of invasive mechanical ventilation. It is unknown if the use of doxapram improves the long-term outcome. This forms the clinical equipoise of the current trial. This international, multicentre trial will provide the needed high-quality evidence on the efficacy and safety of doxapram in the treatment of AOP in preterm infants. TRIAL REGISTRATION: ClinicalTrials.gov NCT04430790 and EUDRACT 2019-003666-41. Prospectively registered on respectively June and January 2020.
引用
- Poppe JA, Flint RB, Smits A, et al. Doxapram versus placebo in preterm newborns: a study protocol for an international double blinded multicentre randomized controlled trial (DOXA-trial). Trials. 2023. PMID: 37817255. doi:10.1186/s13063-023-07683-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。